Massachusetts Medical Society

SHERPA: Blue

People

  1. Motzer
    Motzer
  2. Zauber
    Zauber
  3. Offit
    Offit
  4. Winawer
    Winawer
  5. Hudis
    Hudis
  6. Postow
    Postow
  7. Sepkowitz
    Sepkowitz
  8. Ladanyi
    Ladanyi
  9. Norton
    Norton
  10. Robson
    Robson

Groups

  1. Department of Medicine (327)
  2. Solid Tumor Oncology Division (209)
  3. GSK Faculty (112)
  4. Hematologic Malignancies, Division of (86)
  5. Center for Hematologic Malignancies (84)
  6. Population Sciences Research Program (80)
  7. Survivorship Research (76)
  8. Epidemiology and Biostatistics (65)
  9. Surgery (64)
  10. Sloan Kettering Institute Faculty (58)
Search Within
Formats
  1. Journal Article (517)
  2. Correspondence (27)
  3. Editorial (23)
  4. Research Letter (8)
  5. Review (4)
Groups
  1. Department of Medicine (327)
  2. Solid Tumor Oncology Division (209)
  3. GSK Faculty (112)
  4. Hematologic Malignancies, Division of (86)
  5. Center for Hematologic Malignancies (84)
  6. Population Sciences Research Program (80)

More Groups

People
  1. Robert Motzer (25)
  2. Jedd Wolchok (22)
  3. Peter Bach (18)
  4. Ann Zauber (15)
  5. Kenneth Offit (14)
  6. Sidney Winawer (14)

More People

Years
  1. 2025 (13)
  2. 2024 (16)
  3. 2023 (31)
  4. 2022 (27)
  5. 2021 (24)
  6. 2020 (14)

More Years

Publications
  1. New England Journal of Medicine (574)
  2. NEJM Evidence (4)
  3. Cellular Therapy and Transplantation (1)

Results (579)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Epigenetic therapy in a rare ovarian cancer - A double-edged sword
    Correspondence

    Hsu, C.; Konner, J. A.; Gounder, M. M.
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults
    Journal Article

    Litzow, M. R.; Sun, Z.; Mattison, R. J.; Paietta, E. M.; Roberts, K. G.; Zhang, Y.; Racevskis, J.; Lazarus, H. M.; Rowe, J. M.; Arber, D. A.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Neoadjuvant treatment of mismatch repair–deficient colon cancer — Clinically meaningful?
    Editorial

    Cercek, A.
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Prostate Cancer Foundation screening guidelines for Black Men in the United States
    Review

    Garraway, I. P.; Carlsson, S. V.; Nyame, Y. A.; Vassy, J. L.; Chilov, M.; Fleming, M.; Frencher, S. K. Jr; George, D. J.; Kibel, A. S.; King, S. A.; more...
    NEJM Evidence (2024)

    Fulltext@MSK | Save
  • Adjuvant immunotherapy for kidney cancer - A new strategy with new challenges
    Editorial

    Voss, M. H.; Motzer, R. J.
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
    Journal Article

    Powles, T.; Valderrama, B. P.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Actionable genotypes and life span in Iceland - To the edtior
    Correspondence

    Jee, J.
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Federal oversight of laboratory-developed tests
    Correspondence

    Sholl, L. M.; Adem, P.
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer
    Journal Article

    Drilon, A.; Camidge, D. R.; Lin, J. J.; Kim, S. W.; Solomon, B. J.; Dziadziuszko, R.; Besse, B.; Goto, K.; de Langen, A. J.; Wolf, J.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Three-year overall survival with tebentafusp in metastatic uveal melanoma
    Journal Article

    Hassel, J. C.; Piperno-Neumann, S.; Rutkowski, P.; Baurain, J. F.; Schlaak, M.; Butler, M. O.; Sullivan, R. J.; Dummer, R.; Kirkwood, J. M.; Orloff, M.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save